Patients with Large B-Cell Lymphoma
We Need Your Help!
If you have Large B-Cell Lymphoma and have been treated with Epcoritamab (Epkinly) you can help by completing our survey.
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Quebec equivalent INESSS (Institut national d’excellence en santé et services sociaux). This survey provides us with the patient input required for the submission. CADTH uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
The drug that will soon be reviewed by CADTH/INESSS is Epcoritamab.
Epcoritamab (also known as Epkinly) is a CD3 x CD20 bispecific antibody which recruits T cells to tumor cells – it is administered subcutaneously via injection.
Epcoritamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), including DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a LBCL patient who has not received this therapy.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
It should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!
